Neuroendocrine Tumors

May 20, 2025

FDA Approves First Oral Therapy for Advanced Pheochromocytoma and Paraganglioma

Charles H. Weaver, MD
April 4, 2025

New FDA-Approved Treatment Cabometyx for Advanced Neuroendocrine Tumors

Charles H. Weaver, MD
November 19, 2024

Phase 1b Study Shows Promise for Immunotherapy Plus Chemotherapy in Small Cell Neuroendocrine Tumors

Charles H. Weaver, MD
July 24, 2023

Frequently Asked Questions About Neuroendocrine Tumors

Charles H. Weaver, MD
February 3, 2019

The CancerConnect Neuroendocrine Tumors Newsletter

Charles H. Weaver, MD
August 17, 2018

Lutathera Pepetide Receptor Radionuclide Therapy for NETs

Charles H. Weaver, MD
August 10, 2018

FDA Approves Lutathera for Treatment for Certain Digestive Tract Cancers

Charles H. Weaver, MD
August 7, 2018

Azedra® – Frequently Asked Questions About Azedra® (iobenguane I 131)

Charles H. Weaver, MD
August 3, 2018

FDA Designates Therapy for Azedra in Pheochromocytoma and Paraganglioma

Charles H. Weaver, MD
August 2, 2018

FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors

Charles H. Weaver, MD
August 1, 2018

Lutathera – Improves Outcomes for Neuroendocrine Tumors

Charles H. Weaver, MD
August 1, 2018

Xermelo-new option for controlling symptoms of Carcinoid Syndrome

Charles H. Weaver, MD